<DOC>
	<DOCNO>NCT01717066</DOCNO>
	<brief_summary>Using subject hepatocellular carcinoma conventional therapy evaluate efficacy safety ginsenoside Rg3 ( 20mg BID ) placebo prevention treatment postoperative recurrence liver cancer , respectively</brief_summary>
	<brief_title>Efficacy Safety Ginsenoside Rg3 Capsule Prevention Postoperative Recurrence Hepatocellular Carcinoma</brief_title>
	<detailed_description>1 . Randomized , double-blind , multi-center , placebo-controlled , parallel-group ; 2 . Subject population : patient undergone radical resection hepatocellular carcinoma ; 3 . Active drug group : Ginsenoside Rg3 group : general treatment + ginsenoside Rg3 Control group ( placebo group ) : general treatment + placebo 4.Method group assignment : 5research center , central-block-stratified randomization , ratio active drug group control group : 2:1 5.Dose mode administration : Ginsenoside Rg3 group : ginsenoside Rg3 20mg BID , two month one cycle , continue recurrence occur Placebo Group : placebo , 2 capsule , BID , continue recurrence occur 6.Study period : Screening phase : screening enrollment within 8 week radical resection Follow : review every 2-3 month follow surgery Post-trial investigation : within 28 day trial end recurrence occurs</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Hepatocellular</mesh_term>
	<mesh_term>Recurrence</mesh_term>
	<criteria>1875 year old , male female Mainly base criterion liver cancer TNM stage I II ( edition 7 ) BCLC stage A , follow need satisfy : 1. individual tumor large equal 2 cm small equal 10 cm maximum diameter 2. multiple tumor three tumor 3 . No macroscopic tumor embolus ECOG performance state 01 ChildPugh grade A The clinical review confirm absence recurrence within 8 week enrollment Sign inform consent Pregnant breastfeed woman Patients severe disease brain , heart , lung , kidneys hematological system Patients receive antitumor therapy surgery ( include liver transplantation , TACE , local tumor ablation , chemotherapy , radiotherapy , molecular target therapy antitumor therapy ) DDS chemotherapy pump place portal vein surgery Patients participate drug trial Patients know suspected allergic ginsenoside , history allergy biological preparation , allergic constitution currently allergic state ; With active severe clinical infection Epilepsy episode need drug therapy With history allotransplantation ; With previous history tumor system , except : 1 . Carcinoma situ cervix 2 . Basal cell carcinoma treatment , Superficial bladder cancer ( Ta , Tis T1 3 . Any cancer curative treatment less three year ago Patients sign history bleed diathesis Patients currently receive kidney dialysis A history bleed gastrointestinal tract within 30 day , severe gastroesophageal varix red sign ; history gastroesophageal variceal hemorrhage Recurrent HCC Patients unable take drug orally Patients inappropriate participate trial upon investigator 's judgment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>Hepatocellular Carcinoma</keyword>
	<keyword>ginsenoside Rg3</keyword>
</DOC>